Please assess the completion status of the following clinical trial:

Trial Title: Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed unifocal or multifocal supratentorial WHO grade II astrocytoma (diffuse fibrillary, protoplasmic, or gemistocytic), oligodendroglioma, or oligoastrocytoma~* Patients with neurofibromatosis are eligible~* No other low-grade histologies, including:~  * Pilocytic astrocytoma~ * Subependymal giant cell astrocytoma of tuberous sclerosis~ * Subependymoma~ * Pleomorphic xanthoastrocytoma~ * Presence of a neuronal element such as ganglioglioma~ * Dysneuroembryoplastic epithelial tumor~* No presence of any high-grade glioma, including:~  * Anaplastic astrocytoma~ * Glioblastoma multiforme~ * Anaplastic oligodendroglioma~ * Anaplastic oligoastrocytoma~* No tumors in nonsupratentorial or other locations including optic chiasm, optic nerve(s), pons, medulla, cerebellum, or spinal cord~* No evidence of spread to spinal meninges or noncontiguous cranial meninges (i.e., leptomeningeal gliomatosis)~* No gliomatosis cerebri~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Hematopoietic:~* For high-risk patients:~  * Granulocyte count at least 1,500/mm\^3~ * Platelet count normal~Hepatic:~* Bilirubin no greater than 2 times normal~* SGOT or SGPT no greater than 4 times normal~* Alkaline phosphatase no greater than 2 times normal~Renal:~* Creatinine no greater than 2 times normal~Pulmonary:~* No chronic lung disease (unless DLCO at least 60%)~Neurological:~* Neurologic function score no greater than 3~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to the head or neck (unless brain is clearly excluded, such as radiotherapy for localized vocal cord cancer)~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): Observation only.
- Radiation therapy (Type: EXPERIMENTAL): Radiation therapy only.
- Radiation plus PCV chemotherapy (Type: EXPERIMENTAL): Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).